未找到相关数据
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
被引：33
作者：
Abou-Alfa, Ghassan K.
Meyer, Tim
Cheng, Ann-Lii
El-Khoueiry, Anthony B.
Rimassa, Lorenza
Ryoo, Baek-Yeol
Cicin, Irfan
Merle, Philippe
Park, Joong-Won
Blanc, Jean-Frederic
Bolondi, Luigi
Klumpen, Heinz Josef
Chan, Stephen Lam
Dadduzio, Vincenzo
Hessel, Colin
Borgman-Hagey, Anne E.
Schwab, Gisela
Kelley, Robin Kate
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] UCL, London, England
[3] Natl Taiwan Univ Hosp, Taipei, Taiwan
[4] USC Keck, Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Humanitas Clin & Res Ctr, Rozzano, Italy
[6] Univ Ulsan, Asan Med Ctr, Seoul, South Korea
[7] Trakya Univ, Sch Med, Edirne, Turkey
[8] Groupement Hospitalier Lyon Nord, Lyon, France
[9] Natl Canc Ctr, Goyang, South Korea
[10] Hop St Andre, Bourdeaux, France
[11] IRCCS, Ist Oncol Veneto, Padua, Italy
[12] Acad Med Ctr, Amsterdam, Netherlands
[13] Sir YK Pao Ctr Canc, State Key Lab Oncol S China, Hong Kong, Peoples R China
[14] Univ Oberta Catalunya, Ist Oncologico Veneto, IRCCS, Padua, Italy
[15] Exelixis Inc, San Francisco, CA USA
[16] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.207
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 [肿瘤学];
摘要：
207
引用
收藏
页数：1
相关论文